Form 4: Metagenomi Executive Jian Irish Reports Stock and Option Awards

Jian Irish, President and COO of Metagenomi, reports the acquisition of restricted stock units and stock options.

Summary

• On April 1, 2024, Jian Irish, President and COO of Metagenomi, acquired 70,471 shares of common stock in the form of restricted stock units (RSUs) at $0.00 per share.
• These RSUs vest 25% on June 5, 2025, and the remainder in 12 equal quarterly installments thereafter, contingent upon continued service with the Issuer.
• On the same date, Irish also acquired options to purchase 296,308 shares of common stock at an exercise price of $10.82.
• These options vest 25% on April 1, 2025, and the remainder in 36 equal monthly installments thereafter, contingent upon continued service with the Issuer.
• Irish also indirectly owns 178,483 shares through the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and 178,482 shares through the Jian Irish 2023 Irrevocable Trust, but disclaims beneficial ownership except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a common practice and generally viewed favorably as it aligns executive interests with shareholder value. There are no explicitly negative aspects presented in the document.

Positives

• The granting of RSUs and stock options to a key executive like the President and COO can be seen as an incentive to align their interests with the long-term success of the company.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continued service with the Issuer.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity-based compensation to incentivize their leadership teams.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the granting of RSUs and stock options positively, as it incentivizes management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates